Marc Beer obtained his BS from the University of Miami (Ohio). He is currently the CEO and co-founder of the company Renovia, a start-up that’s primary focus is on women’s health and pelvic floor disorders. Beer has over 25 years of experience in commercialization and development in many industries including pharmaceuticals, devices, biotechnology, and diagnostics.
Prior to his position at Renovia, Marc Beer has held many other lucrative positions including the Vice President of Global Marketing for the company Genzyme. Later, he worked for Abbott Laboratories, performing well in various sales and marketing roles. Beer was also the founding CEO of ViaCell in April of 2000. While at ViaCell, Beer sat on the board of directors for the company Erytech Pharma. He has also been a member of the Mass Life Science Board of the Commonwealth of Massachusetts. Beer has been a founding chairman at Good Start Genetics, Inc. and Minerva Neurosciences, Inc.
In April, Renovia had obtained their first FDA approval of the new product, Leva. Renovia has been researching and developing therapeutic and diagnostic solutions for pelvic floor disorders for women, such as urinary incontinence, which affects over 250 million women worldwide.
More recently, Renovia has received over $42 million in funds to further their research. They plan to use the funding to develop four more products, which will include an updated version of their first product, Leva. While $32 million of the funding came from a Series B round, $10 came from venture debt. The Longwood Fund, a firm that invests in healthcare companies and has been investing in Renovia since the beginning, jumped in the Series B round along with Perceptive Advisors, a New York-based firm, and Ascension Ventures, a Missouri-based firm. Learn more: https://renoviainc.com/
Marc Beer has stated that he is excited to begin this project with their new investors. Renovia’s passion to help patients by using innovative technologies and the digital healthcare platform will greatly influence how much they are able to help their customers who treat patients. The funding and research will enable Renovia to develop products that will yield more knowledge about pelvic floor disorders. This information will help to lower healthcare costs for every aspect of treatment.